Epidermal Growth Factor (EGFR) tests [Tissue-based EGFR PCR Mutation Test] for diagnosis of EGFR mutations in patients with NSCLC
Cycle 4 | Clinical Equipment and DevicesHTA Council Recommendation (as of 18 March 2026)
As final recommendation, the HTA Council recommends tissue-based EGFR PCR Mutation Test for the diagnosis of EGFR mutations in patients with non-squamous NSCLC; and, for patients diagnosed with squamous NSCLC aged <50 years old, regardless of smoking history, for government financing. The Council further recommends adherence to the recommended specimen by the WHO to be used in testing [i.e., Formalin-Fixed, Paraffin-Embedded (FFPE) tissue].
Relevant Information
- Status:With Final HTA Council Recommendation and SOH Decision
- Topic Assignment: Internal Assessment
- Policy Question: Should tissue-based EGFR PCR Mutation Test for the diagnosis of EGFR mutations in patients with non-squamous NSCLC; and, for patients diagnosed with squamous NSCLC aged <50 years old, regardless of smoking history, for government financing be funded by the government?
- Secretary of Health Decision: Approved as of 30 April 2026
Evidence and Relevant Documents